SPOTLIGHT: Symphogen pockets $25M

Danish biotech Symphogen has rounded up $25 million in its fourth round of venture capital, with Takeda Research Investment joining the investment group. Symphogen has a lead candidate now poised to enter the clinic and three other projects in earlier stages. Symphogen also has a few out-licensing deals in the works, telling BioWorld it expects to have two deals inked this year. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.